Medical 24/7: Making Healthcare Affordable for Everyone, Everywhere
Claver Misago is passionate about affordable healthcare. Born into poverty, he was concerned by the prohibitive costs of healthcare and the inability of so many...
: Citizens Financial Group to stop originating indirect auto loan business on July 1, but will service existing loans
Citizens Financial Group Inc. CFG said Wednesday it will stop originating indirect auto loans to car dealers as of July 1 as part of an...
: Bank of Canada hikes rates, ending ‘pause’
The Bank of Canada on Wednesday hiked interest rates by a quarter of a percentage point, resuming tightening after a four-month pause. The bank lifted...
: EIA reports weekly decline in U.S. crude supplies, product inventories rise
The Energy Information Administration on Wednesday reported that U.S. commercial crude inventories edged down by 500,000 barrels for the week ended June 2. That compared...
: Tesla stock rises again, toward longest win streak in more than 2 years
Shares of Tesla Inc. TSLA rallied 3.0% toward a seven-month high in premarket trading Wednesday, which also puts them on track for a ninth-straight gain....
: U.S. stocks open slightly higher after trade deficit data
U.S. stocks opened slightly higher Wednesday as investors digested data showing the U.S. trade deficit widened sharply in April. The Dow Jones Industrial Average DJIA...
Millionaires see market volatility, inflation among biggest threats to wealth, CNBC survey finds
CNBC's latest millionaire survey reveals the biggest threats to personal wealth. Here are the best ways to protect from these risks, according to experts.
: Ollie’s stock rises on boosted adj. profit view
Ollie’s Bargain Outlet Holdings Inc. OLLI stock is up 3% in premarket trades Wednesday after the closeout merchandise retailer boosted its fiscal 2024 outlook for...
: FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trial
Shares of FibroGen Inc. FGEN were down 5.6% premarket on Wednesday after the company announced disappointing results from a late-stage trial of pamrevlumab in non-ambulatory...